Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
22/26/22	$0.000000	-	3
17/26/17	$0.000000	-	5

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 09:55:32 01/06/2026 pm IST			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		-.--%	-

29/12	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/25/21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Market Cap	1L 88.95T 82.72T 75.91T 1L 97.53L 1L 10L 4L 47.95L 4L 4L 1.66Cr	P/E 2022	-0.98x	P/E 2023	-0.18x
Enterprise Value	1.13Cr 99.54L 92.57L 84.95L 1.6Cr 109.14Cr 1.62Cr 11Cr 4.29Cr 54Cr 4.25Cr 4.16Cr 185.52Cr	EV / Sales 2022	-	EV / Sales 2023	1,12,78,456x
Free-Float	89.34%	Yield 2022 *	-	Yield 2023	-

29/12	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/25/21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
14/25/14	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
15/25/15	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
01/25/01	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
30/25/30	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
16/24/16	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
18/24/18	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
15/24/15	Top Midday Decliners	MT
15/24/15	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
27/24/27	Top Midday Decliners	MT
25/24/25	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
25/24/25	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

21/23/21	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
21/23/21	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
21/23/21	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
16/23/16	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
24/23/24	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

Seelos Therapeutics, Inc. Share Price

Stocks

SEELQ

US81577F4063

Biotechnology & Medical Research

Valuation: Seelos Therapeutics, Inc.

Chart: Seelos Therapeutics, Inc.

Latest news : Seelos Therapeutics, Inc.

Analysts' recommendations: Seelos Therapeutics, Inc.

Press Releases: Seelos Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Seelos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

22/24/22	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
25/24/25	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
25/24/25	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
15/24/15	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
15/24/15	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

Current year	0		0.01
1 year	0		0.01
3 years	0		6,374.41
5 years	0		10,713.61
10 years	0		28,761.63

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	01/01/2019
Michael Golembiewski DFI	Director of Finance/CFO	54	01/09/2021
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
29/02/24	Michael Golembiewski	Free	Chief Financial Officer	417	0.0043%
12/01/24	Raj Mehra	Free	Chief Executive Officer	70,383	0.7186%
12/01/24	Michael Golembiewski	Free	Chief Financial Officer	24,537	0.2505%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEELOS THERAPEUTICS, INC.	+9,900.00%	-.--%	-.--%	-100.00%	136
ARGENX SE	+0.93%	+6.97%	+59.60%	+68.35%	5.73TCr
WUXI APPTEC CO., LTD.	-1.92%	+6.03%	+40.64%	+83.42%	5.5TCr
INSMED INCORPORATED	-0.46%	-1.29%	+2.86%	+428.78%	2.32TCr
BIONTECH SE	-2.97%	-2.35%	-22.53%	-16.40%	2.26TCr
WUXI BIOLOGICS (CAYMAN) INC.	-0.36%	+5.73%	+24.13%	-6.24%	2.05TCr
GENMAB A/S	-1.34%	+0.51%	+26.03%	-29.41%	1.76TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.44%	+5.67%	+38.77%	+504.71%	1.57TCr
PHARMAESSENTIA CORPORATION	-1.30%	-5.02%	+170.77%	+291.37%	1.45TCr
EXELIXIS, INC.	-0.50%	-0.98%	+21.43%	+180.07%	1.39TCr
Average	+989.06%	+1.15%	+36.17%	+140.47%	2.4TCr
Weighted average by Cap.	-0.87%	+2.10%	+39.70%	+133.49%

	2022	2023
Net sales	-	2.2 1.93 1.8 1.65 3.1 212.15 3.15 21.37 8.35 104.3 8.27 8.09 360.62
Net income	-7.35Cr -6.46Cr -6.01Cr -5.51Cr -10Cr -708.14Cr -11Cr -71Cr -28Cr -348.15Cr -28Cr -27Cr -1.2TCr	-3.79Cr -3.33Cr -3.09Cr -2.84Cr -5.33Cr -364.81Cr -5.42Cr -37Cr -14Cr -179.35Cr -14Cr -14Cr -620.11Cr
Net Debt	45.89L 40.31L 37.48L 34.4L 64.63L 44Cr 65.62L 4.45Cr 1.74Cr 22Cr 1.72Cr 1.69Cr 75Cr	1.12Cr 98.65L 91.74L 84.19L 1.58Cr 108.17Cr 1.61Cr 11Cr 4.26Cr 53Cr 4.22Cr 4.13Cr 183.86Cr